期刊文献+

参七汤干预冠心病支架植入术后再狭窄临床研究 被引量:5

Clinical Study of Shenqi Decoction in Treating Restenosis after Implantation of Stents in Patients with Coronary Artery Disease
下载PDF
导出
摘要 目的观察参七汤对冠心病支架植入术后炎症免疫反应、机体免疫状态以及再狭窄的影响,并探讨其作用机理。方法冠心病支架植入术后患者88例,采用随机、对照方法分为治疗组45例和对照组43例。对照组采用西医常规治疗,治疗组在其基础上加用参七汤,疗程6个月,观察再狭窄发生率、超敏C-反应蛋白(hsCRP)、活化的T淋巴细胞(CD3+/HLA-DR+)、可溶性白细胞介素-2受体(SIL-2R)及血瘀证、气虚证积分。结果治疗组再狭窄率低于对照组(P<0.05)。冠状动脉介入术后,CD3+/HLA-DR+较术前降低,SIL-2R、hsCRP较术前升高,治疗组治疗后CD3+/HLA-DR+水平较对照组升高(P<0.01),SIL-2R、hsCRP水平较对照组降低(P<0.01),血瘀证积分和气虚证积分亦显著低于对照组(P<0.01),且持续到术后6个月。结论参七汤能有效减少冠心病冠状动脉介入术后再狭窄的发生。减少支架引起的炎症免疫反应,调节机体免疫状态,是其预防冠状动脉介入术后再狭窄的机制之一。 Objective To observe the effect of Shenqi Decoction on inflammation and immune reaction, immune state, restenosis (RS) after implantation of stents in patients with coronary artery disease, and to investigate its mechanism. Methods Eighty-eight patients with coronary artery disease after implantation of stents were randomly divided into the treatment group (45 cases) and the control group (43 cases). The control group was treated with routine treatment, and the treatment group was treated with Shenqi Decoction additionally for six months. RS rate, the level of hs-CRP, the marker of activation of T lymphocytes (CD3^+/HLA^-DR^+), sIL-2R and the scores of blood-stasis syndrome and deficiency of Qi syndrome were observed. Results The RS rate in the treatment group was lower than that in the control group (P〈0.05). After PCI, the level of CD3^+/HLA^-DR^+ was lower while hs-CRP and sIL-2R was higher than before. After treatment with Shenqi Decoction, the level of CD3^+/HLA^-DR^+ and hs-CRP was obviously advanced, and sIL-2R was obviously degraded than that of control group (P〈0.01). The scores of blood-stasis syndrome and deficiency of Qi syndrome in the treatment group was significantly lowered compared with that in the control group (P〈0.01), and remained to 6 months. Conclusion Shenqi Decoction can effectively reduce the occurrence of RS after PCI. Reducing the inflammation and immune reaction of the stents and regulating the immune state is one of its mechanisms.
出处 《中国中医药信息杂志》 CAS CSCD 2010年第2期18-20,共3页 Chinese Journal of Information on Traditional Chinese Medicine
基金 广东省中医药管理局课题(2060007)
关键词 参七汤 冠心病 支架内再狭窄 炎症免疫反应 T淋巴细胞活化 Shenqi Decoction coronary artery disease in-stent restenosis inflammation and immune reaction T lymphocytes activation
  • 相关文献

参考文献16

  • 1Garza L, AudeYW, SaucedoJF. Can we prevent in-stent restenosis[J]. Curr Op in Cardiol,2002,17(5): 518.
  • 2陈灏珠.内科学[M]:第3版[M].北京:人民卫生出版社,1995.350-357.
  • 3中国中西医结合学会心血管病学会.冠心病中医诊断标准.中西医结合杂志,1991,11(5):257-257.
  • 4中国中西医结合研究会活血化瘀专业委员会.血瘀证诊断标准[J].中西医结合杂志,1987,(3):129-129.
  • 5沈自尹 王文健.中医虚证辨证参考标准[J].中西医结合杂志,1986,6(10):598-598.
  • 6王阶,陈可冀.活血化瘀研究与临床[M].北京:北京医科大学、中国协和医科大学联合出版社,1993:7-12.
  • 7潘毅.心气虚证计量诊断再探[J].广州中医学院学报,1995,12(1):10-13. 被引量:20
  • 8李晓涛,夏岳.炎症反应在冠脉支架置入术后再狭窄中的研究进展[J].心血管病学进展,2007,28(5):703-706. 被引量:12
  • 9Osada M, Takeda S, Ogawa R. T lymphocyte activation and restenosis after percutaneous transluminal coronary angioplasty[J]. J Interferon Cytokine Res, 2001,21(4): 219--221.
  • 10Muller KM, Schmitz F. Morphological findings after stent implantation in the carotid artery[J]. Pathologe, 2004,25(2): 108--115.

二级参考文献74

  • 1吴伟康,侯灿,罗汉川,卢景雰,杨正红.垂体后叶素性心肌缺血模型再探[J].中国病理生理杂志,1993,9(2):124-128. 被引量:95
  • 2中国中西医结合研究会活血化瘀专业委员会.血瘀证诊断标准[J].中西医结合杂志,1987,(3):129-129.
  • 3王阶.血瘀证诊断标准的研究[A].见:陈可冀主编.活血化瘀研究与临床[C].北京:北京医科大学中国协和医科大学联合出版社,1993.7.
  • 4中国中西医结合学会心血管病学会.冠心病中医诊断标准.中西医结合杂志,1991,11(5):257-257.
  • 5唐其柱,黄从新,江洪,李庚山,许家利,王晋明.经皮冠状动脉腔内成形术对血浆内皮素-1和6-酮-前列腺素F_(1α)含量的影响[J].中国危重病急救医学,1997,9(2):83-84. 被引量:1
  • 6Rayn TJ,Faxon DP,Gunnar RM,et al.Guidelines for percutaneous transluminal coronary angioplasty:A report of the American College of Cardiology American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty).J Am Coll Cardiol 1988; 12:529.
  • 7Ellis SG,Vandormael MG,Cowley M J,et al.Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease.Implications for patient selection.Circulation 1999 ;82:1193.
  • 8Degertekin M,Serruys PW,Foley DP,et al.Persistant inhi bition of neointimal hyperplasia after sirolimus-eluting stent implantation:long term (up to 2 years) clinical,angiographic,and intravascular ultrasound follow-up.Circulation 2002; 106:1610-1613.
  • 9Morice MC,Serruys PW,Sousa JE,et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.N Engl J Med 2002; 346:1773-1780.
  • 10Waksman R.Drug-eluting stents:from bench to bed.Cardiovasc Radiat Med 2002; 3 (3-4):226-241.

共引文献908

同被引文献108

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部